In addition, inhibition of OC activity by bisphosphonates, RANK-Fc, and osteoprotegerin have been observed to prevent not only MM-induced bone destruction but also MM tumor expansion in MM animal models [18,80,81], suggesting that potent anti-resorptive therapy blunts a vicious cycle between osteoclastic bone destruction and MM tumor expansion. Here, TNFRSF11A is linked to Miyoshi myopathy.